• Policy
• New PVA operation system will be implemented from May
• by Lee, Tak-Sun Apr 30, 2024 05:49am

• Policy
• Gov’t discloses draft for overseas drug price reevals
• by Lee, Tak-Sun Apr 29, 2024 05:50am

• Company
• Patients request Leqembi’s reimb even before approval
• by Eo, Yun-Ho Apr 29, 2024 05:50am

• Opinion
• [Reporter’s View] Patients are left to suffer amid dispute
• by Lee, Jeong-Hwan Apr 29, 2024 05:50am

• Policy
• Jardiance under review for expanding reimb to kidney disease
• by Lee, Tak-Sun Apr 29, 2024 05:49am

• Company
• After 9 years, greenlight for 'Ilaris' reimbursement likely
• by Eo, Yun-Ho Apr 29, 2024 05:49am

• Company
• A change in the DPP4 diabetes market worth KRW 600 billion
• by Kim, Jin-Gu Apr 26, 2024 05:48am

• Company
• ‘HTL is the best global partner for Korean companies'
• by Lee, Seok-Jun Apr 26, 2024 05:48am

• Policy
• Pharma companies with 'superior R&D·K-made drug ingredients
• by Lee, Jeong-Hwan Apr 26, 2024 05:48am

• Company
• LG Chem-EuBiologics will locally manufacture vaccines
• by Kim, Jin-Gu Apr 26, 2024 05:47am